| Not Yet Recruiting | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer NCT07414992 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Not Yet Recruiting | Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC NCT07353294 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 |
| Not Yet Recruiting | Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer NCT06727214 | Sara Mahmoud Ahmed Mahmoud | — |
| Recruiting | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Ca NCT06263153 | Yuanquan Yang | Phase 2 |
| Not Yet Recruiting | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer NCT06528483 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Not Yet Recruiting | ALDOA Expression in Bladder Urothelial Carcinoma NCT06550947 | Assiut University | — |
| Recruiting | Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB) NCT07029256 | Mayo Clinic | — |
| Withdrawn | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer N NCT05564416 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Completed | A Study of CDX-585 in Patients With Advanced Malignancies NCT05788484 | Celldex Therapeutics | Phase 1 |
| Recruiting | Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct NCT06416319 | Universitätsmedizin Mannheim | N/A |
| Recruiting | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastat NCT05296564 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Unknown | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma NCT05220124 | Tianjin Medical University Second Hospital | Phase 4 |
| Terminated | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib NCT05052372 | xCures | — |
| Terminated | Milademetan in Advanced/Metastatic Solid Tumors NCT05012397 | Rain Oncology Inc | Phase 2 |
| Terminated | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors NCT04985604 | Day One Biopharmaceuticals, Inc. | Phase 2 |
| Unknown | En Bloc TURBT With Collins Loop vs Conventional TURBT NCT05027412 | Hospital Universitario de Fuenlabrada | N/A |
| Active Not Recruiting | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Du NCT04216290 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) NCT04574960 | University Health Network, Toronto | Phase 3 |
| Unknown | Safety Analysis and Oncological Outcomes in HoLERT vs TURBT NCT05833997 | Instituto do Cancer do Estado de São Paulo | N/A |
| Completed | Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial NCT04570410 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Completed | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies NCT04440943 | Celldex Therapeutics | Phase 1 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Unknown | Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy NCT04129606 | Abdelwahab Hashem | N/A |
| Active Not Recruiting | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Can NCT03775265 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer NCT03912818 | Stanford University | Phase 2 |
| Active Not Recruiting | Can VI-RADS/ADC Accurately Stage Bladder Cancer?? NCT04167631 | Mansoura University | N/A |
| Active Not Recruiting | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Loca NCT03601455 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer NCT03473730 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Terminated | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection f NCT03266900 | University Health Network, Toronto | EARLY_Phase 1 |
| Unknown | Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC NCT03138824 | Mansoura University | N/A |
| Unknown | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcino NCT03113266 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Completed | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers NCT02989064 | Adaptimmune | Phase 1 |
| Completed | Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy NCT03039413 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Active Not Recruiting | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourin NCT02496208 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma NCT01968928 | National Taiwan University Hospital | — |
| Recruiting | Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. NCT06167356 | IRCCS San Raffaele | — |
| Recruiting | Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy NCT06170177 | IRCCS San Raffaele | — |
| Completed | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery f NCT00238420 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystec NCT00072137 | National Cancer Institute (NCI) | Phase 1 |